Suchergebnisse - "Schmid, Peter"

PubPharm (633)

91

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130) : updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2020

von Schmid, P. | Rugo, H. | Adams, S. | +13

CommentIn: Lancet Oncol. 2020 Jan;21(1):3-5. - PMID 31786122

92

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130) : updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The lancet / Oncology | 2020

von Schmid, P. | Schneeweiss, A.

93

Pembrolizumab for Early Triple-Negative Breast Cancer

enthalten in: The New England journal of medicine | 2020

von Schmid, P. | Cortes, J. | Pusztai, L. | +18

94

Enhancing global access to cancer medicines

enthalten in: CA: A Cancer Journal for Clinicians | 2020

von Cortes, J. | Perez‐García, J. | Llombart‐Cussac, A. | +13

95

Die hard : timberline conifers survive annual winter embolism

enthalten in: New Phytologist | 2020

von Mayr, S. | Schmid, P. | Beikircher, B. | +2

96

TMTpro : Design, Synthesis, and Initial Evaluation of a Proline-Based Isobaric 16-Plex Tandem Mass Tag Reagent Set

enthalten in: Analytical chemistry | 2019

von Thompson, A. | Wölmer, N. | Koncarevic, S. | +13

97

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer : The MANTA Phase 2 Randomized Clinical Trial

enthalten in: JAMA oncology | 2019

von Schmid, P. | Zaiss, M. | Harper-Wynne, C. | +29

ErratumIn: JAMA Oncol. 2021 Feb 1;7(2):312. - PMID 33300961

98

Homo naledi cranial remains from the Lesedi chamber of the rising star cave system, South Africa

enthalten in: Journal of human evolution | 2019

von de Ruiter, D. | Laird, M. | Elliott, M. | +4

99

IMpassion132 Phase III trial : atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer

enthalten in: Future oncology (London, England) | 2019

von Cortés, J. | André, F. | Gonçalves, A. | +9

100

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Bachelot, T. | Ciruelos, E. | Schneeweiss, A. | +111

CommentIn: Ann Oncol. 2019 May 1;30(5):665-667. - PMID 30888412